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Table 1. Changes in Bone Mineral Density
Myeloablative Regimen N 5 30 Reduced Intensity Regimen N 5 20
Day 100 BMD Follow up BMD Change (%/year) Day 100 BMD Follow up BMD Change (%/year) p
BMD spine (g/cm2) 1.159 1.139 21.4% 1.024 1.031 0.8% 0.152
T score spine 20.4 20.6 21.5 21.5
Z score spine 20.3 20.5 21.2 21.2
BMD left hip (g/cm2) 1.009 0.962 24.5% 0.946 0.901 25.0% 0.850
T score left hip 20.4 20.7 20.9 21.3
Z score left hip 20.2 20.5 20.5 20.9
BMD right hip (g/cm2) 0.997 0.963 25.6% 0.936 0.900 25.5% 0.859
T score right hip 20.5 20.7 20.9 21.3
Z score right hip 20.2 20.5 20.6 20.9
BMD left femoral neck (g/cm2) 0.964 0.917 24.0% 0.905 0.853 26.7% 0.598
T score left femoral neck 20.7 21.0 21.2 21.6
Z score left femoral neck 20.3 20.6 20.4 20.9
BMD right femoral neck (g/cm2) 0.955 0.918 25.5% 0.912 0.865 26.7% 0.537
T score right femoral neck 20.7 21.0 21.2 21.5
Z score right femoral neck 20.3 20.6 20.4 20.8
Fracture incidence 0 3 0 0
Table 1. Patient Characteristics
n 5 46
Mean age (range) 48 (21-69)
Sex (%)
Male 30 (65)
Underlying diagnosis (%)
Acute myelogenous leukemia 20 (43.5)
S354 Poster Session IIMethods: IRB approval and patient consent were obtained prior to
review of electronic medical records and Mayo Clinic HSCT data-
base. Adult patients receiving an allogeneic HSCT from 1/1/2007
to 7/15/2010 with two dual-energy x-ray absorptiometry (DEXA)
scans were included. Patients were excluded if they refused research
consent; had a diagnosis of myelofibrosis or multiple myeloma, or no
DEXA scan within 30 days of day 100. Osteoporosis was defined as
a T score less than or equal to -2.5; osteopenia was defined as a T
score -2.4 to -1.5. Baseline demographics and risk factors known
to impact bone density were collected.
Results: From 1/1/2007 to 7/15/2010, 200 patients received an allo-
geneic HSCT; 74 were excluded: 29 myelofibrosis or multiple mye-
loma patients; 14 expired before day 100; 27 had no DEXA scan; 4
refused research consent. In 126 patients with a day 100 BMD,
25% had osteopenia, 17% had osteoporosis, and 12% had fractures.
Fifty patients had a day 100 and second DEXA scan: 30 MA and 20
RIC. The median age at transplant in RIC versus MA was 59 years
versus 45 years, respectively. Changes in BMD and fracture inci-
dence are reported in Table 1. Mean duration between day 100
and second DEXA was 0.92 years. Between day 100 and the second
DEXA,most patients (78%) received steroids and 22% received a bi-
sphosphonate.
Conclusions: There is no difference in BMD between day 100 and
follow-up in patients receiving MA versus RIC allogeneic HSCT.
Lack of observed difference may be due to age, pre-transplant
bone loss, or bisphosphonate use.Myelodysplastic syndrome 4 (9)
Acute lymphoblastic leukemia 1 (2)
Chronic myelogenous leukemia 6 (13)
Chronic lymphocytic leukemia 7 (15)
Lymphoma 4 (9)
Other malignancies 4 (9)
HLA matching (%)
Matched 40 (87)
1-antigen mismatch 5 (11)
2-antigen mismatch 1 (2)
Donor source (%)
Related 15 (33)
Unrelated 31 (67)
Stem cell type (%)
Peripheral blood 42 (91)
Bone marrow 4 (9)
CMV serostatus (%)
D+/R+ 8 (17)
D+/R- 6 (13)
D-/R+ 9 (20)
D-/R- 23 (50)
Conditioning regimen (%)
Bu/Cy 12 (26)
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A RETROSPECTIVE EVALUATION OF DACLIZUMAB FOR THE MANAGE-
MENT OF STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN
ADULTS
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Steroid-refractory graft-versus-host disease (GVHD) in alloge-
neic stem cell transplant patients carries a poor prognosis with lim-
ited options for effective therapy. Daclizumab, a humanized
monoclonal antibody to the alpha subunit of the interleukin-2 (IL-
2) receptor, has been used for the treatment of steroid-refractory
GVHD, with varied response rates noted in the literature. To
date, we have treated and retrospectively reviewed 44 adults who re-
ceived 46 courses of daclizumab for GVHD unresponsive to or pro-
gressing on corticosteroids between January 2006 and July 2009 at
our institution. Five doses of daclizumab (1 mg/kg) were adminis-
tered during a course of therapy on days 1, 4, 8, 15, and 22. Table
1 describes the patient characteristics. GVHD diagnosis was made
a median of 54.5 days (range 12 – 1247 days) and daclizumab was ini-tiated a median of 69 days (range 23 – 1276 days) after transplant.
Prior to daclizumab, patients had the following distribution of organ
involvement: 59% skin, 70% gastrointestinal (GI), and 43% liver,
with 72% of patients having multi-organ involvement. At baseline,
grades 1, 2, 3, and 4 GVHD (IBMTR grading system) were found
in 2%, 12%, 43%, and 43% of patients respectively. At day 28 of da-
clizumab, overall response rate was 28% with 14% of patients
achieving a complete response, 14% with a partial response, 9.5%
with stable disease, and 57% with GVHD progression. Overall sur-
vival at day 28 and 1 year after daclizumabwas 74% and 22%, respec-
tively. Fifteen percent of patients remain alive. Primary causes of
death include relapsed malignancy (15%), treatment-related mortal-
ity (63%), respiratory failure (2%), metastatic melanoma (2%), and
unknown causes (2%). Data evaluating the effect of daclizumab on
chronic liverGVHDwith bile duct dropout is limited, but this subset
Table 1. (Continued )
n 5 46
Cy/SD TBI 18 (39)
Flu/Bu 2 (4)
Flu/Bu/Thymo 6 (13)
fTBI/Cy 5 (11)
Other 3 (7)
GVHD prophylaxis (%)
FK +/2 MTX +/2 MMF 40 (87)
CSA +/2 MTX +/2 MMF 6 (13)
Corticosteroid dose administered (%)
< 1 mg/kg/day 2 (4)
$ 1 mg/kg/day - <2 mg/kg/day x $ 3
days
18 (39)
$ 2 mg/kg/day x $ 3 days 26 (56.5)
Organ involvement of GVHD (%)
Skin 27 (59)
GI 32 (70)
Liver 20 (43.5)
Multi-organ 33 (72)
Daclizumab doses administered (%)
5 33 (72)
4 5 (11)
3 3 (6.5)
# 2 5 (11)
Poster Session II S355of patients may be preferentially responsive to daclizumab. Addi-
tional analysis is ongoing assessing the impact of daclizumab on liver
GVHD.562
MANAGEMENT STRATEGIES FOR ALLOGENEIC HEMATOPOETIC STEM
CELL TRANSPLANT (HSCT) GRAFT VERUS HOST DISEASE (GVHD) PRO-
PHYLAXIS IN THE SETTING OF CALCINEURIN INHIBITOR (CNI) TOXICITY
Harnicar, S.1, Mathew, S.1, Adel, N.1, Giralt, S.2, Jakubowski, A.2 1Me-
morial Sloan-Kettering Cancer Center, New York, NY; 2Memorial
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Background: Calcineurin inhibitors have become the standard of
care for the prophylaxis of acute graft versus host disease, however
both cyclosporine and tacrolimus can cause adverse effects. While
many of these adverse reactions are dose dependent, others may re-
quire alternate prophylaxis therapy. Strategies can be performed to
minimize CNI toxicity: target lower CNI serum levels, change to an-
other CNI, change to a steroid based regimen, or change to a siroli-
mus and/or mycophenolate (MMF) regimen. The current study
sought to evaluate the incidence of GVHD as well as survival in
a group of patients who were unable to continue therapeutic calci-
neurin inhibitor prophylaxis.
Methods: Allogeneic HSCT patients $ 18 years of age who
received cyclosporine or tacrolimus based GVHD prophylaxis
from Jan. 2007 through May 2010 at Memorial Sloan-Kettering
Cancer Center were examined in this retrospective analysis.Table 1. Calcineurin Inhibitor Changes and GVHD
Development/Death
CNI CHANGES N 5 35
GVHD,
N (%)
GRADE III-IV
GVHD, N (%)
GVHD
DEATHS,
N (%)
MEDIAN
DAY TO GVHD
DEATH
LOW TARGET
BASED
6 2 (33) 1 (17) 1 (17) 79
CNI CHANGE 12 6 (50) 2 (17) 2 (17) 280
STEROID BASED 6 2 (33) 0 (0) 1 (17) 245
SIROLIMUS/MMF
BASED
11 6 (55) 3 (27) 4 (36) 91Patients were required to have a change in their prophylaxis regi-
men by one of the strategies previously listed prior to day +100.
Low target CNI was defined as # 5 ng/mL for tacrolimus and #
200 ng /mL for cyclosporine. CNIs must have been used for pro-
phylaxis and not treatment of GVHD. Patients were excluded if
they did not engraft or developed GVHD after day +110. Patient
information was obtained from the pharmacy database and elec-
tronic medical records. Data included demographics, oncologic di-
agnosis, type of transplant, conditioning regimen, GVHD
prophylaxis regimen, and day to GVHD development and death.
Reason for death was verified by use of the Copelan Criteria and
assessed through Aug. 2010.
Results:Out of a possible 293 patients identifed, 35 patients met the
inclusion criteria. Seventeen underwent HSCT for a leukemia diag-
nosis and 18 either had lymphoma or another hematologic neoplastic
disorder. Fifty-one percent (18/35) of patients received a tacrolimus
based regimen and 49% (17/35) received cyclosporine initially. The
majority of CNI prophylactic regimen changes were due to acute re-
nal failure (63%). As illustrated in Table 1, the incidence of GVHD
for the four alternative prophylaxis strategies ranged from 33-55%.
Deaths attributable to GVHD were most frequent in the Siroli-
mus/MMF arm (36%) and occurred before day +100.
Conclusion: Outcomes in this limited patient population suggest
caution with the use of sirolimus or MMF as an alternative GVHD
prophylaxis regimen early post transplant for patients with CNI tox-
icity.563
INFECTIOUS COMPLICATIONS ASSOCIATED WITH THE USE OF ANTITHY-
MOCYTE GLOBULIN IN REDUCED INTENSITY ALLOGENEIC TRANS-
PLANTS
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Introduction Rationale for ATG: Reduced intensity conditioning
(RIC) allogeneic (allo) regimens frequently use antithymocyte glob-
ulin (ATG) for graft versus host disease (GVHD) prevention espe-
cially in unrelated donor (URD) stem cell transplants (SCT) and
mismatched related (mMRD) donor transplants where risk of
GVHD is thought to occur at higher frequency. Use of ATG is fre-
quently associated with infectious complications outweighing bene-
fit of GVHD prevention.
Patients: We retrospectively analyzed 42 patients who underwent
RIC allo SCT between January 2001 and December 2009. Addi-
tionally, we have transplanted 20 RIC allo SCT patients from Jan-
uary 2010 to October 2010 for whom we will have mature data to
report. The mean age was 58 years and majority of male patients
with M:F ratio of 14:7 compared to 16:5 in the ATG versus non
ATG group. All of the patients receiving regimens without ATG
received a MRD allo SCT with the majority (. 90%) of patients
receiving ATG received URD allo SCT. Two patients (9.5%) re-
ceived ATG in view of mismatched related donor transplants. Dis-
ease states requiring SCT with ATG was AML 61.9%, MDS 19%,
NHL 9.5% and SCT without ATG was AML 47.6%, MDS
28.6%, CML 9.5%.
Results:The overall rate of infection in patients who received ATG
was around 90% versus 62%. Bacterial infections were the most
documented infection (61.9% vs 52.4%) and 14.2% of patients had
documented fungal infections in each group. Forty three percent
of patients receiving ATG developed viral infections (n 5 9) versus
19% in those not receiving ATG (n5 4). Documented fungal infec-
tions were the same between both groups (n 5 3, 14.2%). Docu-
mented viral infections were more in the ATG group (28.5% vs
19%). During the engraftment period there were more infections
in patients who received ATG versus those that did not, 14.2% vs
4.8%. Acute GVHD was more prevalent in the ATG group
(23.8% vs 14.3%) and chronic GHVD was greater in the non
ATG group (28.6% vs 14.3%).
Conclusion: There is a greater incidence of infections, primarily
bacterial and viral, in patients treated with ATG versus those that
are not. More studies need to be conducted to determine the
